Acorda Announces 2016 AMPYRA Net Sales And 2017 Financial Guidance At J.P. Morgan Healthcare Conference
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) reported AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg net sales for the fourth quarter of 2016 of $132 million. Full-year net sales for 2016 were $493 million, an increase of approximately 13% from 2015. Final results are subject to completion of the Company’s year-end audit.